Excision BioTherapeutics
Excision BioTherapeutics, San Francisco, CA, develops CRISPR-based therapeutics to cure viral infectious diseases. The company is the first in history to remove viral genomes from animals and achieve functional cures in HIV. Excision’s pipeline includes potential cures for JC virus/PML, Hepatitis B, Herpes Simplex, and SARS-CoV-2. The foundational technology is exclusively licensed from Jennifer Doudna’s lab at UC Berkeley and Kamel Khalili’s lab at Temple University. To date, Excision raised >$80M from venture firms including Artis, GreatPoint, Norwest, Cota, Adjuvant and others. The company is preparing to begin Phase 1/2 trials in 2021.
